Company Diamyd Medical AB

Equities

DMYD B

SE0005162880

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Diamyd Medical AB

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Stockholm Other stock markets 11:29:36 2024-05-17 am EDT			5-day change	1st Jan Change
12.02 ^SEK	+0.50%		+10.48%	+82.95%

May. 16	Diamyd Medical AB Updates on the Registrational Phase 3 Trial	CI
Apr. 18	Diamyd Medical Raises SEK57 Million in Rights Issue	MT

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Number of employees: 26

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	0	100.0 %	1	100.0 %	+20.26%

SEK in Million	2022	Weight	2023	Weight	Delta
Sweden 100.0 %	0	100.0 %	1	100.0 %	+20.26%

Managers	Title	Age	Since
Ulf Hannelius CEO	Chief Executive Officer	49	16-04-09
Anders Essen-Möller FOU	Founder	83	95-12-31
Anna Styrud DFI	Director of Finance/CFO	63	09-12-31
Christoph Nowak CTO	Chief Tech/Sci/R&D Officer	38	20-12-31
Anton Lindqvist CTO	Chief Tech/Sci/R&D Officer	44	12-12-31
Martina Widman COO	Chief Operating Officer	43	16-08-31
Markus Jerling CTO	Chief Tech/Sci/R&D Officer	72	-
Eva Karlström LAW	General Counsel	60	20-07-31

Members of the board	Title	Age	Since
Anders Essen-Möller FOU	Founder	83	95-12-31
Erik Kjellsson Nerpin BRD	Director/Board Member	63	11-12-31
Karin Hehenberger BRD	Director/Board Member	52	21-04-27
Carl Torbjörn Bäckström BRD	Director/Board Member	76	17-03-31
Maria-Teresa Essen-Möller BRD	Director/Board Member	54	08-12-31
Mark Atkinson BRD	Director/Board Member	63	18-11-14
Karin Rosen BRD	Director/Board Member	57	23-03-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,741,630	0	0	63.20 %
Stock B	1	92,206,366	60,009,544 ( 65.08 %)	0

Name	Equities	%	Valuation
Bertil Lindkvist 8.351 %	7,700,000	8.351 %	7 M kr
Anders Essen-Möller 3.207 %	2,957,040	3.207 %	3 M kr
Maria-Teresa Essen-Möller 1.045 %	963,998	1.045 %	938 009 kr
Konstruktions o Försäljningsaktiebolaget KFAB 0.9828 %	906,250	0.9828 %	881 818 kr
Moller Jon Essen 0.4370 %	402,987	0.4370 %	392 122 kr
Moller Martin Essen 0.3237 %	298,513	0.3237 %	290 465 kr
Erika Hillborg 0.2858 %	263,537	0.2858 %	256 432 kr
Ulf Hannelius 0.2576 %	237,500	0.2576 %	231 097 kr
My Essenshaw 0.1963 %	181,002	0.1963 %	176 122 kr
Anna Styrud 0.1491 %	137,499	0.1491 %	133 792 kr

Name	Equities	%	Valuation
Anders Essen-Möller 21.76 %	556,223	21.76 %	541 227 kr
Moller Martin Essen 15.65 %	400,000	15.65 %	389 216 kr
My Essenshaw 15.65 %	400,000	15.65 %	389 216 kr
Moller Jon Essen 15.65 %	400,000	15.65 %	389 216 kr
Erika Hillborg 15.65 %	400,000	15.65 %	389 216 kr
Maria-Teresa Essen-Möller 15.65 %	400,000	15.65 %	389 216 kr

Diamyd Medical AB

Kungsgatan 29

111 56, Stockholm

+46 86 61 00 26

http://www.diamyd.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
DIAMYD MEDICAL AB	+82.95%	115M
VERTEX PHARMACEUTICALS INCORPORATED	+8.89%	114B
REGENERON PHARMACEUTICALS, INC.	+11.47%	104B
BIONTECH SE	-12.69%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-3.15%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+8.12%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.69%	12.55B

Bio Therapeutic Drugs